Roche’s Gazyva, which first reached the market as a blood cancer drug, has expanded its FDA approval to include treatment of the autoimmune disorder lupus nephritis. The CD20-targeting antibody can now compete against a blockbuster GSK drug that is the standard biologic therapy for the debilitating kidney condition.
The post FDA Approval for Roche Cancer Drug Brings a New Biologic Option to Lupus Nephritis appeared first on MedCity News.
